Boston Scientific presents new TAXUS data

19 October 2008

US vascular devices maker Boston Scientific has presented the results of an analysis of the HORIZONS AMI trial on the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in patients experiencing acute myocardial infarction, at the Cardiovascular Research Foundation's Transcatheter Cardiovascular Therapeutics symposium in Washington DC.

One-year results from the 3,006-patient, prospective, large, international, randomized clinical trial comparing the Taxus system with a bare-metal stent, showed comparable overall safety outcomes (death, stroke, myocardial infarction or stent thrombosis) between the two treatment groups (8.0% for the bare-metal stent versus 8.1% for the TAXUS stent, p=0.92). There was a statistically-significant 41% reduction in revascularization in the TAXUS group (7.5% for the ordinary stent vs 4.5% for TAXUS, p=0.002). Subjects will be followed for five years to ensure that the results are maintained.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight